{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:40:55Z","timestamp":1791560455025,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cl\u00e9ment Fayat Foundation"},{"name":"the Innovative Medicines Initiative 2 Joint Undertaking","award":["116060 (IMPRiND)"],"award-info":[{"award-number":["116060 (IMPRiND)"]}]},{"name":"the Innovative Medicines Initiative 2 Joint Undertaking","award":["116060 (IMPRiND)"],"award-info":[{"award-number":["116060 (IMPRiND)"]}]},{"name":"the Innovative Medicines Initiative 2 Joint Undertaking","award":["116060 (IMPRiND)"],"award-info":[{"award-number":["116060 (IMPRiND)"]}]},{"name":"Wellcome Trust and the Royal Society","award":["206248\/Z\/17\/Z"],"award-info":[{"award-number":["206248\/Z\/17\/Z"]}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French government in the framework of the University of Bordeaux\u2019s IdEx \u201cInvestments for the Future\u201d program","award":["GPR BRAIN_2030"],"award-info":[{"award-number":["GPR BRAIN_2030"]}]},{"name":"Bettencourt-Schueller Foundation"},{"name":"PSP-France Foundation"},{"name":"Center of Excellence for Neurodegenerative Diseases in Bordeaux"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-00938-9","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:58:23Z","timestamp":1744509503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques"],"prefix":"10.1038","volume":"11","author":[{"given":"Morgane","family":"Darricau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Kulifaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Arotcarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Katsinelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Xilouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Dehay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.pneurobio.2015.07.003","volume":"155","author":"M Bourdenx","year":"2017","unstructured":"Bourdenx, M. et al. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: examples of amyloidopathies, tauopathies and synucleinopathies. Prog. Neurobiol. 155, 171\u2013193 (2017).","journal-title":"Prog. Neurobiol."},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin, D. et al. Cognitive and pathological influences of tau pathology in lewy body disorders. Ann. Neurol. 85, 259\u2013271 (2019).","journal-title":"Ann. Neurol."},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J., Lee, V. M.-Y. & Trojanowski, J. Q. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat. Rev. Neurosci. 14, 626\u2013636 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson, J. L. et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain 144, 953\u2013962 (2021).","journal-title":"Brain"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/mp.2015.6","volume":"20","author":"RS Desikan","year":"2015","unstructured":"Desikan, R. S. et al. Genetic overlap between Alzheimer\u2019s disease and Parkinson\u2019s disease at the MAPT locus. Mol. Psychiatry 20, 1588\u20131595 (2015).","journal-title":"Mol. Psychiatry"},{"key":"938_CR6","doi-asserted-by":"publisher","unstructured":"Chu, Y. et al. Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain awad388 https:\/\/doi.org\/10.1093\/brain\/awad388. (2023)","DOI":"10.1093\/brain\/awad388"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/brain\/aww230","volume":"140","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Masuda-Suzukake, M. & Falcon, B. Like prions: the propagation of aggregated tau and \u03b1-synuclein in neurodegeneration. Brain 140, 266\u2013278 (2017).","journal-title":"Brain"},{"key":"938_CR8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem, S. S. et al. \u03b1-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl. Acad. Sci. USA 119, e2109617119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"938_CR9","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"eaaz9165","DOI":"10.1126\/sciadv.aaz9165","volume":"6","author":"M Bourdenx","year":"2020","unstructured":"Bourdenx, M. et al. Identification of distinct pathological signatures induced by patient-derived \u03b1-synuclein structures in nonhuman primates. Sci. Adv. 6, eaaz9165 (2020).","journal-title":"Sci. Adv."},{"key":"938_CR11","doi-asserted-by":"publisher","unstructured":"Darricau, M. et al. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain awac428 https:\/\/doi.org\/10.1093\/brain\/awac428. (2022)","DOI":"10.1093\/brain\/awac428"},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys: LB-Induced Pathology. Ann. Neurol. 75, 351\u2013362 (2014).","journal-title":"Ann. Neurol."},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/alz.13604","volume":"20","author":"M Darricau","year":"2024","unstructured":"Darricau, M. et al. Tau seeds from Alzheimer\u2019s disease brains trigger tau spread in macaques while oligomeric-A\u03b2 mediates pathology maturation. Alzheimer\u2019s Dement. 20, 1894\u20131912 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/brain\/awab374","volume":"145","author":"M Teil","year":"2022","unstructured":"Teil, M. et al. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain 145, 1001\u20131017 (2022).","journal-title":"Brain"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41531-023-00579-w","volume":"9","author":"M Teil","year":"2023","unstructured":"Teil, M. et al. Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain. NPJ Parkinsons Dis. 9, 135 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"938_CR16","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1084\/jem.20160833","volume":"213","author":"JL Guo","year":"2016","unstructured":"Guo, J. L. et al. Unique pathological tau conformers from Alzheimer\u2019s brains transmit tau pathology in nontransgenic mice. J. Exp. Med. 213, 2635\u20132654 (2016).","journal-title":"J. Exp. Med."},{"key":"938_CR17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192193","volume":"218","author":"F Bassil","year":"2021","unstructured":"Bassil, F. et al. \u03b1-Synuclein modulates tau spreading in mouse brains. J. Exp. Med. 218, e20192193 (2021).","journal-title":"J. Exp. Med."},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","volume":"21","author":"E Bezard","year":"2001","unstructured":"Bezard, E. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque model of Parkinson\u2019s Disease. J. Neurosci. 21, 6853\u20136861 (2001).","journal-title":"J. Neurosci."},{"key":"938_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1385\/MN:28:3:209","volume":"28","author":"W Meissner","year":"2003","unstructured":"Meissner, W. et al. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of parkinson\u2019s disease. Mol. Neurobiol. 28, 209\u2013218 (2003).","journal-title":"Mol. Neurobiol."},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"938_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker, L. et al. Neuropathologically mixed Alzheimer\u2019s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 129, 729\u2013748 (2015).","journal-title":"Acta Neuropathol."},{"key":"938_CR22","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"938_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000502","volume":"30","author":"T Lebouvier","year":"2017","unstructured":"Lebouvier, T., Pasquier, F. & Bu\u00e9e, L. Update on tauopathies. Curr. Opin. Neurol. 30, 589\u2013598 (2017).","journal-title":"Curr. Opin. Neurol."},{"key":"938_CR24","doi-asserted-by":"publisher","unstructured":"Barba, L. et al. Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in Lewy body disease. Brain awae203 https:\/\/doi.org\/10.1093\/brain\/awae203 (2024)","DOI":"10.1093\/brain\/awae203"},{"key":"938_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41592-019-0470-3","volume":"16","author":"J Ho","year":"2019","unstructured":"Ho, J. et al. Moving beyond P values: data analysis with estimation graphics. Nat. Methods Jul. 16, 565\u2013566 (2019).","journal-title":"Nat. Methods Jul."},{"key":"938_CR26","doi-asserted-by":"publisher","unstructured":"Laurens J. The statistical power of three monkeys. bioRXiv. https:\/\/doi.org\/10.1101\/2022.05.10.491373 (2022)","DOI":"10.1101\/2022.05.10.491373"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00938-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00938-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00938-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T14:01:54Z","timestamp":1744552914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00938-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-00938-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.B. is a director and shareholder of Motac Neuroscience Ltd. During the past 3 years, V.P. was a local unpaid investigator or sub-investigator for clinical trials granted by Novo Nordisk, Biogen, Janssen, and Alector. V.P. served as a consultant for Motac Neuroscience Ltd, outside the submitted work. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}